Diverse Manifestations of Sickle Cell Disease
Biree Andemariam, MD
Caroline Freiermuth, MD
Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan
Keeping Pace in Hematologic Malignancies: 2023Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
Harry Paul Erba, MD, PhD
Courtney DiNardo, MD
Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
Joseph Mikhael, MD
Monique Hartley-Brown, MD
Brandon Blue, MD
In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer
John L. Marshall, MD
Late-Stage Bispecifics and ADCs in DLBCL
Sarah Rutherford, MD
John P. Leonard, MD
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
Alex Herrera, MD
Alison J. Moskowitz, MD
Application of Data from the ECHELON-1 Trial
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Kami Maddocks, MD
Matthew J. Matasar, MD
NCCN Guideline Updates in DLBCL
Antibody-Drug Conjugates in FL
Individualizing Frontline Treatment
Patient Selection for ADCs in First-Line DLBCL
Bispecific Antibodies in FL
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
Treatment Options for Invasive Fungal Infections: Why They Don't Always Work
Thomas F. Patterson, MD, FACP, FIDSA
George Thompson III, MD, FIDSA
Loading...
We’re glad to see you’re enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.